Malignant uterine smooth muscle tumors: role of etoposide, cisplatin, and doxorubicin (EPA) chemotherapy.

Abstract

BACKGROUND:

Nearly 80% of patients with malignant uterine smooth muscle tumor will suffer local relapse and/or distant metastases after initial surgical resection. There is no convincing evidence that the addition of pelvic radiation improves the outcome. However, adjuvant chemotherapy might be an appropriate therapeutic modality.

METHODS:

Between 1986 and 1991, 13 consecutive patients with malignant uterine smooth muscle tumors were treated at Yale-New Haven Hospital with a combination chemotherapy containing etoposide 100 mg/M2 on days 1 and 2, cisplatin 50 mg/M2 on day 1, and doxorubicin 50 mg/M2 on day 1, repeated every 28 days. Six patients had Stage I disease, one patient had Stage III disease, and six patients had Stage IV disease. The number of cycles ranged from 2 to 9.

RESULTS:

The median follow-up was 30 months (range 4-81). The mean overall survival for the group was 43.1 +/- 6.7 months, with the progression-free interval of 25.5 +/- 8.0 months. Of the seven patients with evaluable disease, one patient had complete response and one had partial response (total response rate of 28.6%). Of the six patients treated adjuvantly, three recurred at 9, 33, and 59 months (recurrence rate of 50%).

CONCLUSIONS:

We conclude that this combination has only modest activity against malignant uterine smooth muscle tumors at the schedule and doses tested.

• Authors: E Resnik, S K Chambers, M L Carcangiu, E I Kohorn, P E Schwartz, I T Chambers
• Journal: Journal of surgical oncology (J Surg Oncol) Vol. 63 Issue 3 Pg. 145-7 (Nov 1996) ISSN: 0022-4790 [Print] United States
• PMID: 8944057 (Publication Type: Journal Article)

Chemical References

• Antibiotics, Antineoplastic
• Antineoplastic Agents, Phytogenic
• Etoposide
• Doxorubicin
• Cisplatin

Topics

• Adult
• Aged
• Antibiotics, Antineoplastic (administration & dosage)
• Antineoplastic Agents, Phytogenic (administration & dosage)
• Antineoplastic Combined Chemotherapy Protocols (therapeutic use)
• Cisplatin (administration & dosage)
• Doxorubicin (administration & dosage)
• Etoposide (administration & dosage)
• Female
• Humans
• Leiomyosarcoma (drug therapy)
• Middle Aged
• Myometrium
• Neoplasms, Muscle Tissue (drug therapy, pathology)
• Survival Analysis
• Treatment Outcome
• Uterine Neoplasms (drug therapy, pathology)